Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mosunetuzumab plus polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma
2023-506986-74-00Phase 2Authorised
- Sponsor
- Roche
- Start
- Nov 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of mosunetuzumab and polatuzumab vedotin in mature B-cell lymphoma, follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL) and 1 more, sponsored by Roche. Primary endpoints: Occurrence and severity of adverse events, including dose-limiting toxicities, Change from baseline in targeted vital signs and 5 more. Planned start Nov 2023; status: authorised.
02
Drugs
mosunetuzumabpolatuzumab vedotin
03
Conditions
mature B-cell lymphomafollicular lymphoma (FL)diffuse large B-cell lymphoma (DLBCL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2023-506986-74-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506986-74-00.